Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 9/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.61 |
| ▸ | GCK | P35557 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929854 | 0.93 | CXCR2 (0.87) | CXCR2CXCR1GCKMEN1KMT2A | |
| SCHEMBL12398724 | 0.86 | CXCR2 (0.76) | CXCR2CXCR1GCKMEN1KMT2A | |
| SCHEMBL2158636 | 0.86 | CXCR2 (0.80) | CXCR2CXCR1MEN1KMT2A | |
| SCHEMBL6930364 | 0.85 | CXCR2 (0.74) | CXCR2CXCR1MEN1KMT2A | |
| SCHEMBL6927775 | 0.84 | CXCR2 (0.73) | CXCR2CXCR1GCKMEN1KMT2A | |
| SCHEMBL12398731 | 0.84 | CXCR2 (0.72) | CXCR2CXCR1 | |
| SCHEMBL3501765 | 0.82 | CXCR2 (0.69) | CXCR2CXCR1GCKMEN1KMT2A | |
| SCHEMBL6929819 | 0.82 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL6931210 | 0.81 | CXCR2 (0.69) | CXCR2CXCR1GCKMEN1KMT2A | |
| SCHEMBL6927893 | 0.81 | CXCR2 (0.68) | CXCR2CXCR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | CXCR2 2454/4885CXCR1 2582/4885GCK 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.